by
Thomas Dworetzky, Contributing Reporter | January 11, 2017
IBM has been making a number of deals for Watson lately.
Yesterday, IBM announced it had
teamed with Illumina, a leader in DNA sequencing technology, in the interest of advancing precision medicine.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
IBM integrated Watson for Genomics into Illumina's BaseSpace Sequence Hub and TruSight Tumor 170, a tool for profiling solid tumors into a panel aimed at showing a set of variants for 170 different genes. With Watson's help, researchers will be able to take the sequencing information and then scour the literature — from guidelines to clinical trials — to footnote every genetic alteration in a patient's results.
Last December, researchers in India reported that Watson for Oncology (WFO) had shown a
high degree of agreement with the recommendations of a panel of oncologists in a double-blinded validation study.
“Manipal Hospitals recently adopted Watson for Oncology as a tool to support our oncologists in making quality, evidence-based decisions for their patients,” the study’s lead author, Dr. S.P. Somashekhar, chairman of the Manipal Comprehensive Cancer Center of Manipal Hospitals, in Bengaluru, India, reported.
Back to HCB News
